Skip to main content

Congressional Testimony

Peter Axilrod, Managing Director | December 2, 2009

DTCC supports the broad goals of the Administration’s approach to addressing systemic risk. We also share the assessment that meaningful transparency to regulators and the public at large requires that all OTC derivatives either be cleared through a regulated central counterparty or else registered in a regulated repository. But in the area of trade reporting, we believe further refinement is needed to assure that potentially serious unintended consequences are avoided.

Download the Congressional Testimony: Testimony Before U.S. Senate Committee on Agriculture, Nutrition, and Forestry